Pregbio, a Shenzhen-based non-invasive prenatal gene detection company, has reportedly raised an undisclosed amount of money in an angel financing round. The sole contributor to the round was ASB Ventures. The proceeds will be used to promote early screening and diagnosis of preterm labor and pre-eclampsia, non-invasive prenatal screening, and other pipeline products. Additionally, the funds will support the early research and development of new product pipelines and daily company operations.
Company Background and Innovation
Founded in 2020, Pregbio has been at the forefront of discovering and verifying new biomarkers related to the screening and diagnosis of preterm labor and pre-eclampsia. The company has also achieved highly efficient and accurate capture and separation of human trophoblastic stem cells, as well as highly reliable non-invasive prenatal screening. Pregbio’s product pipeline includes early screening and diagnosis of preterm labor and pre-eclampsia, non-invasive prenatal screening of fetal malformations, TORCH detection, and a series of backup pipelines, pregnancy self-test kits, and other consumer-facing products.
Market Context and Future Outlook
The primary users of non-invasive prenatal gene testing are women of childbearing age, particularly those of advanced maternal age. In China, women of advanced maternal age account for 15% of the total, with a 65% non-invasive prenatal gene sequencing rate. The overall average non-invasive prenatal gene sequencing rate stands at 40%. The market is valued at more than 7 billion. With this new funding, Pregbio aims to expand its market presence and enhance its product offerings, addressing the growing demand for reliable prenatal screening solutions.-Fineline Info & Tech
